# ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

> **NCT04620239** · PHASE3 · RECRUITING · sponsor: **Steba Biotech S.A.** · enrollment: 100 (estimated)

## Conditions studied

- Transitional Cell Cancer of Renal Pelvis and Ureter

## Interventions

- **DRUG:** padeliporfin VTP

## Key facts

- **NCT ID:** NCT04620239
- **Lead sponsor:** Steba Biotech S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-22
- **Primary completion:** 2026-03-30
- **Final completion:** 2029-01-25
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620239, "ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04620239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*